Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In the trenches on the medicine wards and smoking cessation clinics at Parkland Hospital  and UT Southwestern Simmons Cancer Center, I see firsthand the increased prevalence of smoking in the Black population, their frequent use of menthol, and the ravaging toll it takes on their health.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
David Balis, MD
Director, Smoking Cessation Clinics, Parkland Hospital, UT Southwestern Simmons Cancer Center; Professor, General Internal Medicine, UT Southwestern
Table of Contents

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
FDA has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor CAR T-cell therapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.  
David Balis, MD
Director, Smoking Cessation Clinics, Parkland Hospital, UT Southwestern Simmons Cancer Center; Professor, General Internal Medicine, UT Southwestern

Login